Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until ...

Roche Holding AG licensed a new weight-loss drug from Zealand Pharma A/S for as much as $5.3 billion, bolstering the Swiss drugmaker’s effort to get into a hot market dominated by Novo Nordisk A/S and ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.

Roller-coaster healthcare stock Hims & Hers Health (NYSE: HIMS), whose stock got devastated last week by worries that it ...

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Eli Lilly's stock fell 4.58% following weak trial results from Novo Nordisk’s obesity drug, shaking investor confidence in ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Three U.S. senators are calling on Robert Kennedy Jr. to disclose what he and President Trump discussed with drugmakers ...